5-HT6 Receptor Antagonist as an Adjunct Treatment Targeting Residual Symptoms in Patients With Schizophrenia: Unexpected Sex-Related Effects (Double-Blind Placebo-Controlled Trial)

No abstract is available for this paper.

• Publication year

  2017

• Venue

  Journal of Clinical Psychopharmacology

• Publication date

  2017-04-01

• Fields of study

  Medicine, Psychology

• Identifiers
  DOI 10.1097/JCP.0000000000000673PMID 28141622
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• AVN-211, Novel and Highly Selective 5-HT6 Receptor Small Molecule Antagonist, for the Treatment of Alzheimer's Disease.

  2016cited by this paper
• Decreased serotonin2C receptor responses in male patients with schizophrenia.

  2015cited by this paper
• 5-HT6 Receptor Antagonists: Potential Efficacy for the Treatment of Cognitive Impairment in Schizophrenia.

  2015cited by this paper
• Idalopirdine as a treatment for Alzheimer’s disease

  2015cited by this paper
• 5-HT6 Receptor Antagonists: Potential Efficacy for the Treatment of Cognitive Impairment in Schizophrenia.

  2015cited by this paper
• Low-dose prazosin in combination with 5-HT6 antagonist PRX-07034 has antipsychotic effects.

  2015cited by this paper
• Olanzapine augments the effect of selective serotonin reuptake inhibitors by suppressing GABAergic inhibition via antagonism of 5-HT₆ receptors in the dorsal raphe nucleus.

  2015cited by this paper
• Effects of Clozapine on Perceptual Abnormalities and Sensory Gating: A Preliminary Cross-Sectional Study in Schizophrenia

  2015cited by this paper
• A phase II/III trial of bitopertin monotherapy compared with placebo in patients with an acute exacerbation of schizophrenia - results from the CandleLyte study.

  2014cited by this paper
• Safety and efficacy of idalopirdine, a 5-HT6 receptor antagonist, in patients with moderate Alzheimer's disease (LADDER): a randomised, double-blind, placebo-controlled phase 2 trial.

  2014cited by this paper
• Signaling mechanisms involved in the acute effects of estradiol on 5-HT clearance.

  2014cited by this paper
• Role of glutamate and advantages of combining memantine with a 5HT_6 ligand in a model of depression

  2014cited by this paper
• Add-on clinical effects of selective antagonist of 5HT6 receptors AVN-211 (CD-008-0173) in patients with schizophrenia stabilized on antipsychotic treatment: pilot study

  2013cited by this paper
• Co-administration of 5-HT6 receptor antagonists with clozapine, risperidone, and a 5-HT2A receptor antagonist: effects on prepulse inhibition in rats

  2013cited by this paper
• Synthesis of substituted diphenyl sulfones and their structure-activity relationship with the antagonism of 5-НТ6 receptors.

  2013cited by this paper
• Targeting glutamate system for novel antipsychotic approaches: relevance for residual psychotic symptoms and treatment resistant schizophrenia.

  2012cited by this paper
• Testosterone and Aggressive Behavior in Man

  2012cited by this paper
• 5-HT6 receptor blockade differentially affects scopolamine-induced deficits of working memory, recognition memory and aversive learning in mice

  2012cited by this paper
• The effects of PRX-07034, a novel 5-HT6 antagonist, on cognitive flexibility and working memory in rats

  2012cited by this paper
• Testosterone and Aggressive Behavior in Man

  2012cited by this paper
• Executive functioning during full and partial remission (positive and negative symptomatic remission) of schizophrenia.

  2012cited by this paper
• Discovery of 7-arylsulfonyl-1,2,3,4, 4a,9a-hexahydro-benzo[4,5]furo[2,3-c]pyridines: identification of a potent and selective 5-HT₆ receptor antagonist showing activity in rat social recognition test.

  2012cited by this paper
• Remitted but still impaired? Symptomatic versus functional remission in patients with schizophrenia

  2012cited by this paper
• Time-course of 5-HT(6) receptor mRNA expression during memory consolidation and amnesia.

  2010cited by this paper
• Second-generation versus first-generation antipsychotic drugs for schizophrenia: a meta-analysis.

  2009cited by this paper
• Sertindole improves sub-chronic PCP-induced reversal learning and episodic memory deficits in rodents: involvement of 5-HT6 and 5-HT2A receptor mechanisms

  2009cited by this paper
• Schizophrenia

  2009cited by this paper
• Recovery in the outpatient setting: 36-month results from the Schizophrenia Outpatients Health Outcomes (SOHO) study.

  2009cited by this paper
• Remission in the outpatient care of schizophrenia: 3-Year results from the Schizophrenia Outpatients Health Outcomes (SOHO) Study in France

  2008cited by this paper
• Norms and standardization of the Brief Assessment of Cognition in Schizophrenia (BACS).

  2008cited by this paper
• Assessment of strategies for switching patients from olanzapine to risperidone: A randomized, open-label, rater-blinded study

  2008cited by this paper
• Standard and Higher Dose of Olanzapine in Patients With Schizophrenia or Schizoaffective Disorder: A Randomized, Double-Blind, Fixed-Dose Study

  2008cited by this paper
• What Is Causing the Reduced Drug-Placebo Difference in Recent Schizophrenia Clinical Trials and What Can be Done About It?

  2008cited by this paper
• Symptomatic remission in previously untreated patients with schizophrenia: 2-year results from the SOHO study

  2007cited by this paper
• A systematic review of longitudinal outcome studies of first-episode psychosis

  2006cited by this paper
• The estrogen 100

  2006cited by this paper
• Cellular and molecular effects of steroid hormones on CNS excitability.

  2004cited by this paper
• Estrogen modulates synaptic N‐methyl‐D‐aspartate receptor subunit distribution in the aged hippocampus

  2004cited by this paper
• Symptomatic and functional recovery from a first episode of schizophrenia or schizoaffective disorder.

  2004cited by this paper
• The Serotonin Hypothesis of Schizophrenia: A Historical Case Study on the Heuristic Value of Theory in Clinical Neuroscience

  2004cited by this paper
• Estrogen enhances depolarization-induced glutamate release through activation of phosphatidylinositol 3-kinase and mitogen-activated protein kinase in cultured hippocampal neurons.

  2003cited by this paper
• Diverse actions of ovarian steroids in the serotonin neural system.

  2002cited by this paper
• Olanzapine in refractory schizophrenia after failure of typical or atypical antipsychotic treatment: an open-label switch study.

  2002cited by this paper
• Newer atypical antipsychotic medication in comparison to clozapine: a systematic review of randomized trials.

  2002cited by this paper
• Is the placebo powerless? An analysis of clinical trials comparing placebo with no treatment.

  2001cited by this paper
• Development, reliability and acceptability of a new version of the DSM‐IV Social and Occupational Functioning Assessment Scale (SOFAS) to assess routine social funtioning

  2000cited by this paper
• Ovarian steroid action on tryptophan hydroxylase protein and serotonin compared to localization of ovarian steroid receptors in midbrain of guinea pigs

  1999cited by this paper
• Androgen actions on central serotonin neurotransmission: relevance for mood, mental state and memory.

  1999cited by this paper
• One hundred years of schizophrenia: a meta-analysis of the outcome literature.

  1994cited by this paper
• Validation of the 16-item Negative Symptom Assessment.

  1993cited by this paper
• The Continuous Performance Test, identical pairs version (CPT-IP): I. New findings about sustained attention in normal families.

  1988cited by this paper
• The positive and negative syndrome scale (PANSS) for schizophrenia.

  1987cited by this paper

• Overview of Novel Antipsychotic Drugs: State of the Art, New Mechanisms, and Clinical Aspects of Promising Compounds

  2025cites this paper
• 5-HT6 receptors: Contemporary views on their neurobiological and pharmacological relevance in neuropsychiatric disorders

  2025cites this paper
• GABAergic and inflammatory changes in the frontal cortex following neonatal PCP plus isolation rearing, as a dual-hit neurodevelopmental model for schizophrenia

  2024cites this paper
• 5-HT6 Receptors Sex-Dependently Modulate Hippocampal Synaptic Activity through GABA Inhibition

  2023cites this paper
• Progress in Investigational Agents Targeting Serotonin-6 Receptors for the Treatment of Brain Disorders

  2023cites this paper
• Pharmacological management of neurocognitive impairment in schizophrenia: A narrative review

  2023cites this paper
• Spatiotemporal dynamics of 5-HT6 receptor ciliary localization during mouse brain development.

  2023cites this paper
• Impact of 5-HT6 Receptor Subcellular Localization on Its Signaling and Its Pathophysiological Roles

  2023cites this paper
• Progress and Pitfalls in Developing Agents to Treat Neurocognitive Deficits Associated with Schizophrenia

  2022influential citation
• Pharmacological Targets and Mechanisms of Action of Antipsychotic Substances in the Context of the Neurochemical Theory of the Pathogenesis of Schizophrenia

  2022cites this paper
• Cognitive Deficit in Schizophrenia: From Etiology to Novel Treatments

  2021cites this paper
• Serotonin Type 6 and 7 Receptors as a Novel Therapeutic Target for the Treatment of Schizophrenia

  2020cites this paper
• Serotonin Type 6 and 7 Receptors as a Novel Therapeutic Target for the Treatment of Schizophrenia

  2020cites this paper
• Serotonin Type 6 and 7 Receptors as a Novel Therapeutic Target for the Treatment of Schizophrenia

  2020cites this paper
• Prediction of the significance in the improvement of depression symptoms of amisulpride in the treatment of schizophrenia: an 8-week case-control study.

  2020cites this paper
• Calbindin Deficits May Underlie Dissociable Effects of 5-HT6 and mGlu7 Antagonists on Glutamate and Cognition in a Dual-Hit Neurodevelopmental Model for Schizophrenia

  2020cites this paper
• Alternative splicing in serotonergic system: Implications in neuropsychiatric disorders

  2019cites this paper
• Efficacy of Asenapine in Schizophrenia Resistant to Clozapine Combined with Electroconvulsive Therapy: A Case Report

  2019cites this paper
• Characterization of Behavioral, Signaling and Cytokine Alterations in a Rat Neurodevelopmental Model for Schizophrenia, and Their Reversal by the 5-HT6 Receptor Antagonist SB-399885

  2018cites this paper